Morton LTC (Morton Drug Company), Neenah, WI

Is Morton LTC (Morton Drug Company) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Morton LTC (Morton Drug Company) hold a Wisconsin pharmacy license?

State board of pharmacy records for Wisconsin are not checked: the Department of Safety and Professional Services shows orders only through a script-driven search behind a user agreement, and its license lookup is an interactive search.

Has Morton LTC (Morton Drug Company) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jun 13, 2019), 1 state referral letter (Jun 13, 2019) and 1 FMD-145 letter (Jun 13, 2019) for Morton LTC (Morton Drug Company). State board of pharmacy records for Wisconsin are not checked: the Department of Safety and Professional Services shows orders only through a script-driven search behind a user agreement, and its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Morton Drug Company; Morton LTC
Location
Neenah, WI
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 13, 2019
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 7 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Morton Drug Company (dba Morton LTC), a 503A facility, with 3 dated actions.

Document
Jun 13, 2019Warning letter close-outWarning Letter Close Out Issued 06/13/2019Not linked by FDA
Jun 13, 2019FMD-145 letterFMD-145 Letter Issued 06/13/2019FDA copy (archived)
Jun 13, 2019State referral letterReferral Letter to the Wisconsin State Board of Pharmacy Issued 06/13/2019FDA copy (archived)

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Morton Drug Company, Neenah, WI (FEI number 3008927138), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 22, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3008927138953460
May 20, 2011Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3008927138724709

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Dec 15, 2015 to Dec 22, 2015: 7 observations

Firm on the cover
Stephen C. Morton, CE O, 201 E. Bell Street, Neenah, W I 5 4956 Firm Na me
FEI number
3008927138
Establishment type on the cover
Producer of S terile D rugs
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding systems for maintaining an)' equipment used to control the aseptic conditions.

Specifically,

A. The “clean room” where the ISO 5 redact ed b4 resides and the ante room are not classi fied . B. The pressure differentials between the “clean room” -ante room and the ant e room - outside room were not mo nito red. C . the Redacted b4 the ISO 5 Redacted b4 are not sterile.

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm did not establish an environmental monitoring procedure and failed to conduct environment monitoring of air, personnel, and surface during daily sterile product preparation within the ISO 5 Redact ed b4 even thoug h the ISO 5 R edacted b4. For example,

A. A ctive viable air monitoring is not performed in the ISO 5 Re dacted b4 during preparation of sterile drug product s. B. Environment monitoring of the IS O 5 Redacte d b4 is not conducted at the end of each day when steril e drug products are prepared . C. Microbiological monitoring of the Redacted b4 is not performed each day after sterile drug product is prep ared . D. The pressure differential results on ISO 5 R edacted b4 were not documented during the preparation of sterile products. E. When the ISO 5 redacted b4. There is no documented evidence demonstrating that the aseptic condition can be Redacted b4 to the unclassified environment.

Observation 3

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, your firm's practice of visual inspection is deficient in that you do not have procedure requiring 100% visual inspection of the finished drug products and documenting the results of such visual inspection. For example,

A. On 12/15/2015, your pharmacy technician, Redacted b6 prepared a batch solution of Cefazolin (batch number 12151ad). A total of redacted b4 bags of the finished product containing 2 g of Cefazolin in 100 mL of 0.9% Sodium Chloride sterile solution were prepared. Upon Completion of the preparation, your pharmacist, Redacted b6 performed verification of the preparation documents and labels. However, neither the pharmacy technician nor the reviewing pharmacist performed visual inspection of the products even though this deficiency has been brought up to the firm’s management attention on 12/15/2015. A. On 12/15/2015, your pharmacy technician, Redacted b6 prepared a batch solution of Cefazolin (batch number 121 51

ad). ...

Read the full 483 (PDF on fda.gov)

Observation 4

Results of stability testing are not used in determining appropriate storage conditions and expiration dates.

Specifically, your firm has prepared Clindamycin sterile drug product with 900 mg Clindamycin in 100 mL 0.9% Sodium Chloride solution on redacted b4. Each day’s preparation generated Redacted b4 bags of products. These products were assigned the beyond use date (BUD) of 9 days at room temperature. There is no stability study demonstrating that this product is stable for 9 days under room temperature. Your firm acknowledged that this BUD was incorrect and should have been assigned not more than 30 hours at room temperature. All redacted b4 bags of this product have been distributed to one patient and have already been administered. Specifically, your firm has prepared Clindamycin sterile drug product with 900 mg Clindamycin in 100 mL 0.9% Sodium Chloride solution on redacted b4. Each day’s preparation generated Redacted b4 bags of products. These products were assigned the beyond use date (BUD) of 9 days at room temperature. There is no stability study demonstrating that this product is stable for 9 days under room temperature. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically, the gowning practice is not sufficient for the sterile drug production operation. Employee requires only a pair of non-sterile glove for the preparation of sterile products. For example,

A On 12/15/2015 prior to preparing batch solution Cefazolin product (batch number 12151ad), your firm’s pharmacy technician, Redacted b4, Redacted b6 unprotected arms, face, neck, hair, and clothing were all exposed Redacted b4. A On 12/15/2015 prior to preparing batch solution Cefazolin product (batch number 12151ad), your firm’s pharmacy

technician, Re dacted b4, Redacted b 6 unprotected arms, face, neck, hair, and clothing were all exposed Redacted b4.

OAIE IS S<ICO

EloiPI.OYUISJ SIGHAT\111£

though Redacted b6 wore a mask du ring the cleaning process. Redacted b6 unprotected arms, part of redacted b6 face, neck, hair and redacted b6 sweater were all exposed Redacted b4.

Observation 6

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically, the media fill studies that were used to validate the aseptic techniques and to qualify individual employee for the sterile product preparation were deficient in that.

A There was no environment monitoring done Redacted b4 the iso 5 Redacted b4 during media fill study. A There was no environment monitoring done Re dacted b4 the iso 5 Redacted b4 during media fill study.B The re cord of media fill re-qualification study conducted on Redacted b4 for pharmacy technician, Redacted b6 showed that the sample incubation temperature reached 38 C which exceeded the acceptable range of Redacted b4 of Redacted b4 C. No investigation was conducted and documented. This media fill study result was accepted as is and the technician was allowed to continue preparing sterile products. To the date of this inspection, this employee has compounded Redacted b6 sterile products since redacted b6 recent re-qualification media fill study on redacted b4. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, the cleaning agent Redacted b4 and Redacted b4 disinfectants Redacted b4 that are used to clean and sanitize the iso 5 Redacted b4 area are not sterile.Specifically, the cleaning a gent Redac ted b4 and Redacted b4 disinfectants Redacted b 4 that are used to clean and sanitize the iso 5 Redacted b4 area are not sterile.Specifically, the cleaning agent Redacted b4 and Redacted b4 disinfectants Redacted b4 that are used to clean and sanitize the iso 5 Redacted b4 area are not sterile.Specifically, the clea ning agent Redacted b4 and Redacted b4 disinfectants Redacted b4 that are used to clean and sanitize the iso 5 Redacted b4 area are not sterile.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Wisconsin are not checked: the Department of Safety and Professional Services shows orders only through a script-driven search behind a user agreement, and its license lookup is an interactive search.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.